Table 2 Antagonistic 2-agents combinations
From: Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials
Agent 1 | Agent 2 | Standard of care* | Expected ORR 1 | Observed ORR 2 | p antagonism | Cancer subtype |
|---|---|---|---|---|---|---|
Docetaxel | Topotecan | No | 42 | 12 | 2.94E-11 | Lung, ovarian cancer |
Bortezomib | Rituximab | No | 78 | 53 | 1.20E-09 | Lymphoma |
Temozolomide | Alpha-interferon | No | 38 | 18 | 5.87E-08 | Melanoma |
Capecitabine | Bortezomib | No | 58 | 14 | 9.02E-08 | Breast cancer |
Fludarabine | Alemtuzumab | No | 83 | 64 | 1.27E-07 | CLL, leukemia |
Bevacizumab | Temozolomide | No | 48 | 16 | 1.41E-07 | Melanoma |
Capecitabine | Trimetrexate | No | 45 | 6 | 2.15E-06 | Colorectal cancer |
Docetaxel | Irinotecan | No | 37 | 18 | 1.15E-05 | Gastric, lung, ovarian cancer |
Bortezomib | Temsirolimus | No | 64 | 30 | 1.25E-05 | Myeloma |
Temozolomide | Interleukin-2 | No | 49 | 16 | 1.97E-05 | Melanoma |
Docetaxel | Gefitinib | No | 71 | 31 | 2.29E-05 | Lung cancer |
Docetaxel | 5-fluorouracil | No | 38 | 25 | 1.71E-04 | Gastric, head and neck cancer |
Rituximab | Temsirolimus | No | 75 | 59 | 2.44E-03 | Lymphoma |
Temozolomide | Radiation | No | 64 | 46 | 2.51E-03 | Breast cancer |
Fludarabine | Alpha-interferon | No | 76 | 52 | 2.55E-03 | Lymphoma |
G-CSF | Rituximab | No | 71 | 61 | 4.69E-03 | CLL, lymphoma |
Doxorubicin | Bevacizumab | No | 40 | 21 | 9.11E-03 | Breast cancer |
Docetaxel | Imatinib | No | 46 | 28 | 2.09E-02 | Breast cancer |
Docetaxel | Capecitabine | Yes | 49 | 43 | 4.48E-02 | Breast, gastric cancer |
Vinorelbine | Mitoxantrone | No | 42 | 29 | 4.62E-02 | Breast cancer |